Primary Burkitt’s Lymphoma Presenting as a Rapidly Growing Thyroid MassYildiz I.a · Sen F.a · Toz B.b · Kilic L.a · Agan M.c · Basaran M.a
aDepartment of Medical Oncology, Institute of Oncology, and Departments of bInternal Medicine and cPathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Ibrahim Yildiz, MD
Department of Medical Oncology
Institute of Oncology, Istanbul University
TR–21234 Istanbul (Turkey)
Tel. +90 505 746 51 78, E-Mail firstname.lastname@example.org
Do you have an account?
A 31-year-old male patient presented with a rapidly growing neck mass with normal thyroid function tests. Ultrasonography showed thyroidal expansion, a hypoechoic nodule that completely filled the right lobe, and 2 hypoechoic lymphadenopathies in the right jugulodigastric chain. The patient underwent right total and left subtotal thyroidectomy, following the diagnosis of nodular goiter; however, postoperative histopathological evaluation demonstrated primary Burkitt’s lymphoma of the thyroid gland. The tumor was staged as stage 1, and R-hyper-CVAD protocol (rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone) was administered. The protocol was changed to R-CHOP after 4 cycles due to recurrent grade III/IV cytopenias and febrile neutropenia. The PET-CT scans performed after chemotherapy and at the 6-month follow-up were normal. In summary, we reported a case with a diagnosis of Burkitt’s lymphoma, which is a rare type of primary thyroid lymphoma.
© 2012 S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / DisclaimerOpen Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.